Clinical Trial Support
Generate high-quality, regulatory-compliant clinical trial data with our unparalleled sequencing and analysis services.
Power Successful Clinical Trials with Industry-Leading Genomics Expertise
Avoid clinical trial setbacks caused by inconsistent data quality, regulatory compliance challenges, and sample complexities that compromise critical study endpoints. Broad Clinical Labs’ Clinical Trial Support sequencing combines unmatched expertise in challenging samples and rare diseases with comprehensive analysis to deliver the quality regulatory-compliant data that drives successful clinical trial outcomes.
Ensure your study is supported by the gold standard in data quality, backed by genomic leaders who understand that clinical trial timelines demand precision the first time.
Expert Consultation and Regulatory Alignment
Drawing on three decades of genomic innovation, our experts collaborate with you to optimize assay selection and ensure regulatory alignment for your clinical trial. Our scientists provide strategic guidance on sequencing approaches for your study while managing sample logistics and coordination throughout your trial.
Scalable Clinical-Grade Genomic Sequencing
Access our comprehensive portfolio of sequencing services, including Clinical WGS, Clinical WES, and liquid biopsy, performed in our CLIA-licensed and CAP-accredited facility. Our scalable infrastructure and expertise with challenging sample types delivers consistent, regulatory-compliant data that meets the strictest clinical trial standards.
Advanced Analysis & Interpretation
Transform genomic data into actionable clinical insights with our expert bioinformatics analysis and interpretation services. Our scientists provide comprehensive analysis and, for interpretation services, prioritize results based on patient clinical profiles to translate sequencing data into meaningful insights that support critical trial decisions and regulatory submissions.
Experience the Gold Standard in Clinical Trial Genomics
Transparent Collaborative Communication
Stay informed throughout your trial with our clear timelines, regular updates, and transparent communication.
Rapid Turnaround Times
Meet critical trial timelines with our fast turnaround times and streamlined protocols. Our efficient processing ensures your study endpoints aren’t delayed by sequencing bottlenecks.
Automated Workflow Reliability
Ensure consistency and reliability across samples with our automated workflows and rigorous quality controls. Our experienced project management teams maintain data integrity at any scale, from dozens to thousands of samples.
Rare Disease & Complex Sample Expertise
Advance your challenging clinical trial programs with our specialized expertise in complex sample processing and deep knowledge in rare disease.
Driving Clinical Impact Through Partnerships
From Phase III cancer trials to pioneering vaccine research, our world-class genomic services have empowered leading clinical programs to advance patient care and therapeutic development.
Advancing Multiple Myeloma Clinical Insights
Takeda partnered with Broad Clinical Labs to analyze patient samples from their Phase III multiple myeloma trial of Ninlaro. Through collaborative design of a targeted panel interrogating 754 genes, our expert RNA sequencing and DNA mutational analysis helped Takeda unlock critical insights into multiple myeloma biology and treatment resistance mechanisms.
Powering Personalized Cancer Vaccine Breakthroughs
Broad Clinical Labs provided the sequencing expertise that enabled Dana-Farber Cancer Institute’s groundbreaking phase 1 trial of NeoVaxMI, an updated personalized cancer vaccine for melanoma, published in Cell. Our sequencing capabilities supported research demonstrating improved vaccine-specific immune responses, representing a promising advancement in personalized cancer immunotherapy.
Decoding Sickle Cell Disease
Through comprehensive whole exome sequencing analysis of 1,459 sickle cell disease patients, Broad Clinical Labs supported the Division of Hematologic Neoplasia at Dana-Farber Cancer Institute, whose innovative research identified pivotal insights into hematopoietic stem cell mutations that could impact future gene therapy approaches.